Overview
The aim of the study is to compare the efficacy of using EFA technology versus the combination of EFA + high flow in hypersecretory patients COPD and bronchiectasis
Description
After being informed about the study and potential risks, all patients giving written informed consent will undergo a 13-weeks trial period: 6 weeks of one technology (EFA / EFA+ HIGH FLOW), 1- wash out week and 6- weeks of the other technology in a cross over randomized trial.
Eligibility
Inclusion Criteria:
- COPD diagnosed by spirometry
- Bronchiectasis diagnosed by CT
- 2 Exacerbation/year
Exclusion Criteria:
- Cystic Fibrosis
- OSAS
- Non Invasive Ventilation
- Ineffective Cough
- Exacerbation in progress
- Hemodynamic Instability
- severe heart failure